Critical Review: Avalo Therapeutics (NASDAQ:AVTX) and Allergy Therapeutics (OTCMKTS:AGYTF)

Avalo Therapeutics (NASDAQ:AVTX) and Allergy Therapeutics (OTCMKTS:AGYTF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Avalo Therapeutics and Allergy Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60,000.00	7,881.95	-$78.26 million	($5.46)	-2.95
Allergy Therapeutics	$71.22 million	1.06	-$51.94 million	N/A	N/A

Allergy Therapeutics has higher revenue and earnings than Avalo Therapeutics.

Profitability

This table compares Avalo Therapeutics and Allergy Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Allergy Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for Avalo Therapeutics and Allergy Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1	0	11	0	2.83
Allergy Therapeutics	0	0	0	0	0.00

Avalo Therapeutics currently has a consensus price target of $48.13, suggesting a potential upside of 198.47%. Given Avalo Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Avalo Therapeutics is more favorable than Allergy Therapeutics.

Volatility and Risk

Avalo Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of 12.76, indicating that its stock price is 1,176% more volatile than the S&P 500.

Summary

Avalo Therapeutics beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

About Allergy Therapeutics

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.